SANUWAVE PACE technology reverses negative effects of ischemic, reperfusion injuries

SANUWAVE Health, Inc. (OTCBB: SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today reported publication of peer-reviewed, preclinical data conducted at Cleveland Clinic that demonstrate the ability of the Company's Pulsed Acoustic Cellular Expression (PACE^®) technology to substantially decrease the detrimental effects of microcirculatory injury for certain ischemic (lack of blood flow) and reperfusion (restoration of blood flow) injuries.

“Pulsed Acoustic Cellular Expression as a Protective Therapy Against I/R Injury in a Cremaster Muscle Flap Model”

The authors, including Maria Siemionow, MD, PhD, DSc, demonstrated that a single treatment with PACE technology, delivered either before or after tissue injury, reversed the negative effects of the injury and stimulated recovery of microcirculatory hemodynamics (blood circulation forces) to healthy levels. The publication, titled "Pulsed Acoustic Cellular Expression as a Protective Therapy Against I/R Injury in a Cremaster Muscle Flap Model," has been e-published ahead of press in Microvascular Research.